International Journal of Stem Cells

  • 제16권2호
  • /
  • Pages.215-233
  • /
  • 2023
  • /
  • 2005-3606(pISSN)
  • /
  • 2005-5447(eISSN)
한국줄기세포학회 (Korean Society for Stem Cell Research)
권호 표지
DOI QR코드

DOI QR Code

Alterations and Co-Occurrence of C-MYC, N-MYC, and L-MYC Expression are Related to Clinical Outcomes in Various Cancers

  • Moonjung Lee (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University) ;
  • Jaekwon Seok (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University) ;
  • Subbroto Kumar Saha (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University) ;
  • Sungha Cho (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University) ;
  • Yeojin Jeong (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University) ;
  • Minchan Gil (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University) ;
  • Aram Kim (Department of Urology, Konkuk University Medical Center, Konkuk University School of Medicine) ;
  • Ha Youn Shin (Department of Biomedical Science & Engineering, KU Convergence Science and Technology Institute, Konkuk University) ;
  • Hojae Bae (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University) ;
  • Jeong Tae Do (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University) ;
  • Young Bong Kim (Department of Biomedical Science & Engineering, KU Convergence Science and Technology Institute, Konkuk University) ;
  • Ssang-Goo Cho (Department of Stem Cell and Regenerative Biotechnology & Institute of Advanced Regenerative Science, Konkuk University)
  • 투고 : 2022.11.15
  • 심사 : 2023.02.15
  • 발행 : 2023.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background and Objectives: MYC, also known as an oncogenic reprogramming factor, is a multifunctional transcription factor that maintains induced pluripotent stem cells (iPSCs). Although MYC is frequently upregulated in various cancers and is correlated with a poor prognosis, MYC is downregulated and correlated with a good prognosis in lung adenocarcinoma. MYC and two other MYC family genes, MYCN and MYCL, have similar structures and could contribute to tumorigenic conversion both in vitro and in vivo. Methods and Results: We systematically investigated whether MYC family genes act as prognostic factors in various human cancers. We first evaluated alterations in the expression of MYC family genes in various cancers using the Oncomine and The Cancer Genome Atlas (TCGA) database and their mutation and copy number alterations using the TCGA database with cBioPortal. Then, we investigated the association between the expression of MYC family genes and the prognosis of cancer patients using various prognosis databases. Multivariate analysis also confirmed that co-expression of MYC/MYCL/MYCN was significantly associated with the prognosis of lung, gastric, liver, and breast cancers. Conclusions: Taken together, our results demonstrate that the MYC family can function not only as an oncogene but also as a tumor suppressor gene in various cancers, which could be used to develop a novel approach to cancer treatment.

키워드

과제정보

This paper was supported by Konkuk University Premier Research Fund in 2019.

참고문헌

  1. Mukherjee B, Morgenbesser SD, DePinho RA. Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. Genes Dev 1992;6:1480-1492 
  2. Walker W, Zhou ZQ, Ota S, Wynshaw-Boris A, Hurlin PJ. Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J Cell Biol 2005;169:405-413 
  3. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872 
  4. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 1993;7:671-682 
  5. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 1992;6:2235-2247 
  6. Moens CB, Auerbach AB, Conlon RA, Joyner AL, Rossant J. A targeted mutation reveals a role for N-myc in branching morphogenesis in the embryonic mouse lung. Genes Dev 1992;6:691-704 
  7. Charron J, Malynn BA, Fisher P, Stewart V, Jeannotte L, Goff SP, Robertson EJ, Alt FW. Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev 1992;6:2248-2257 
  8. Hatton KS, Mahon K, Chin L, Chiu FC, Lee HW, Peng D, Morgenbesser SD, Horner J, DePinho RA. Expression and activity of L-Myc in normal mouse development. Mol Cell Biol 1996;16:1794-1804 
  9. Hurlin PJ. Control of vertebrate development by MYC. Cold Spring Harb Perspect Med 2013;3:a014332 
  10. Alitalo K, Bishop JM, Smith DH, Chen EY, Colby WW, Levinson AD. Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci USA 1983;80:100-104 
  11. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982;79:7824-7827 
  12. Sheiness DK, Hughes SH, Varmus HE, Stubblefield E, Bishop JM. The vertebrate homolog of the putative transforming gene of avian myelocytomatosis virus: characteristics of the DNA locus and its RNA transcript. Virology 1980;105:415-424 
  13. Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, McBride OW, Bertness V, Hollis GF, Minna JD. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 1985;318:69-73 
  14. Schwab M, Varmus HE, Bishop JM, Grzeschik KH, Naylor SL, Sakaguchi AY, Brodeur G, Trent J. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 1984;308:288-291 
  15. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116 
  16. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003;22:9007-9021 
  17. Alarcon-Vargas D, Tansey WP, Ronai Z. Regulation of c-myc stability by selective stress conditions and by MEKK1 requires aa 127-189 of c-myc. Oncogene 2002;21:4384-4391 
  18. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002;21:5280-5288 
  19. Noguchi K, Kokubu A, Kitanaka C, Ichijo H, Kuchino Y. ASK1-signaling promotes c-Myc protein stability during apoptosis. Biochem Biophys Res Commun 2001;281:1313-1320 
  20. Popescu NC, Zimonjic DB. Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med 2002;6:151-159 
  21. Kumari A, Folk WP, Sakamuro D. The dual roles of MYC in genomic instability and cancer chemoresistance. Genes (Basel) 2017;8:158 
  22. Tansey WP. Mammalian MYC proteins and cancer. New J Sci 2014;2014:757534 
  23. Rochlitz CF, Herrmann R, de Kant E. Overexpression and amplification of c-myc during progression of human colorectal cancer. Oncology 1996;53:448-454 
  24. Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer 2010;1:629-640 
  25. Uribesalgo I, Benitah SA, Di Croce L. From oncogene to tumor suppressor: the dual role of Myc in leukemia. Cell Cycle 2012;11:1757-1764 
  26. Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 2021;14:121 
  27. Li Y, Casey SC, Felsher DW. Inactivation of MYC reverses tumorigenesis. J Intern Med 2014;276:52-60 
  28. Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, Alt FW. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983;35(2 Pt 1):359-367 
  29. Stoneley M, Chappell SA, Jopling CL, Dickens M, MacFarlane M, Willis AE. c-Myc protein synthesis is initiated from the internal ribosome entry segment during apoptosis. Mol Cell Biol 2000;20:1162-1169 
  30. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001;81:717-723 
  31. Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Baylin SB, Vogelstein B. Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 1986;233:461-464 
  32. Kawashima K, Shikama H, Imoto K, Izawa M, Naruke T, Okabayashi K, Nishimura S. Close correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human lung cancer to the lymph nodes and other organs. Proc Natl Acad Sci U S A 1988;85:2353-2356 
  33. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM, Rubin MA. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013;15:1-10 
  34. Mizukami Y, Nonomura A, Takizawa T, Noguchi M, Michigishi T, Nakamura S, Ishizaki T. N-myc protein expression in human breast carcinoma: prognostic implications. Anticancer Res 1995;15:2899-2905 
  35. Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V, He HH, Brown M, Liu XS, Davis M, Caswell JL, Beckwith CA, Hills A, Macconaill L, Coetzee GA, Regan MM, Freedman ML. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci USA 2010;107:9742-9746 
  36. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer 2010;1:617-628 
  37. Chen CR, Kang Y, Massague J. Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 2001;98:992-999 
  38. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-1607 
  39. Nau MM, Brooks BJ Jr, Carney DN, Gazdar AF, Battey JF, Sausville EA, Minna JD. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci USA 1986;83:1092-1096 
  40. Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC. Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. Cancer Res 2007;67:10677-10685 
  41. Wu R, Lin L, Beer DG, Ellenson LH, Lamb BJ, Rouillard JM, Kuick R, Hanash S, Schwartz DR, Fearon ER, Cho KR. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am J Pathol 2003;162:1603-1610 
  42. Xie S, Shen C, Tan M, Li M, Song X, Wang C. Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer. Oncotarget 2017;8:27216-27239 
  43. Cui X, Jing X, Yi Q, Long C, Tan B, Li X, Chen X, Huang Y, Xiang Z, Tian J, Zhu J. Systematic analysis of gene expression alterations and clinical outcomes of STAT3 in cancer. Oncotarget 2017;9:3198-3213 
  44. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, Garapati P, Hemish J, Hermjakob H, Jassal B, Kanapin A, Lewis S, Mahajan S, May B, Schmidt E, Vastrik I, Wu G, Birney E, Stein L, D'Eustachio P. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 2009;37(Suppl 1):D619-D622 
  45. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331 
  46. Xu AG, Li SG, Liu JH, Gan AH. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. World J Gastroenterol 2001;7:403-406 
  47. Weston A, Caporaso NE, Perrin LS, Sugimura H, Tamai S, Krontiris TG, Trump BF, Hoover RN, Harris CC. Relationship of H-ras-1, L-myc, and p53 polymorphisms with lung cancer risk and prognosis. Environ Health Perspect 1992;98:61-67 
  48. Chen J, Li S, Yang Z, Lu G, Hu H. Correlation between NDRG1 and PTEN expression in endometrial carcinoma. Cancer Sci 2008;99:706-710 
  49. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, Bissell MJ, Bishop JM. MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits. Nat Cell Biol 2012;14:567-574 
  50. Ma X, Huang J, Tian Y, Chen Y, Yang Y, Zhang X, Zhang F, Xue L. Myc suppresses tumor invasion and cell migration by inhibiting JNK signaling. Oncogene 2017;36:3159-3167